However, all patients with GBA1-PD/PDD/DLB have α-synuclein pathology15, suggesting that it is an integral feature of GBA1-PD, and that those individuals who have a GBA1 mutation will be less protected in the event of α-synuclein accumulation. This evidence concerns the gene GBA1 and Parkinson disease.